Objective: Dose optimization of novel β-lactam antibiotics (NBLA) has become necessary
given the increased prevalence of multidrug-resistant infections in intensive care units …

Introduction Several novel beta-lactams (BLs) and/or beta lactams/beta-lactamase inhibitors
(BL/BLIs) have been recently developed for the management of multidrug-resistant bacterial …

The use of antibacterial drugs is very common in critically ill patients and beta-lactam agents
are widely used in this context. Critically ill patients show several characteristics (eg, sepsis …

There is currently an increase in the emergence of multidrug-resistant bacteria (MDR)
worldwide, requiring the development of novel antibiotics. However, it is not only the choice …

Abstract Purpose of Review Beta-lactam antibiotics are commonly prescribed in critically ill
patients for a variety of infectious conditions. Our understanding of how critical illness alters …

Antimicrobials are among the most important and commonly prescribed drugs in the
management of critically ill patients and beta-lactams are the most common antibiotic class …

Infections and related sepsis are two of the most prevalent issues in the care of critically ill
patients, with mortality as high as 70%. Appropriate antibiotic selection, as well as adequate …

Severe sepsis and septic shock can alter the pharmacokinetics of broad-spectrum β-lactams
(meropenem, ceftazidime/cefepime, and piperacillin-tazobactam), resulting in inappropriate …

Background: The aims of this study were to describe pharmacokinetic/pharmacodynamic
target attainment in intensive care unit (ICU) patients treated with continuously infused ß …

Introduction: Emerging studies suggest that antibiotic pharmacokinetics (PK) are difficult to
predict in critically ill patients. The high intra-and inter-patient PK variability makes it …